

JC13 Rec'd PCT/PTO 0 2 JAN 2002

App. use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	
Filing Date	December 31, 2001
First Named Inventor	Hugo A.G.GEERTS
Group Art Unit	
Examiner Name	
Attorney Docket Number	JAB-1515

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			T ²
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
VB		Guo, Q., Sebastian, L., Sopher, B.L., Miller, M.W., Ware, C.B., Martin, G.M., Mattson, M.P., "Increased Vulnerability of Hippocampal Neurons from Presenilin-1 Mutant Knock-In Mice to amyloid Beta-Peptide Toxicity: Central Roles of Superoxide Production and Caspase Activation", Journal of Neurochemistry 1999 pp. 1019-1029	
VB		Goedert, M., Hasegawa, M., "The Tauopathies, Toward an Experimental Animal Model, American Journal of Pathology, 1999 Vol 154 No. 1 pp.1-6.	
VB		Gotz, J., Probst, A., Spillantini, M.G., Schafer, T., Jakes, R., Burki, K. & Goedert, M., "Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform", The EMBO Journal 1995 Vol. 14 No. 7, pp. 1304-1313	
VB		Brion, J.P., Tremp, G., Octave, J.N., "Transgenic Expression of the Shortest Human Tau affects Its Compartmentalization and Its Phosphorylation as in the Pretangle Stage of Alzheimer's Disease, American Journal of Pathology, 1999 Vol. 154, No. 1 pp. 255-270.	
VB		Kuhn, R., Schwenk, F., "Advances in gene targeting methods", Current Opinion in Immunology, 1997 9:183-188	
VB		Sauer, Brian, "Inducible Gene Targeting in Mice Using the Cre/lox System, Methods, A Companion to Methods in Enzymology" 14, 381-392 1998 Art.# ME980593	
VB		Brownlee, J., Irving, N.G. Brion, J.P., Gibb, B.J.M., Wagner U., Woodgett, J., Miller, C.C.J., "Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3(beta) transgenes", NeuroReport 8, pp.3251-3255 1997	
VB		Harada, A., Oguchi, K., Okabe, S., Kuno, J., Terada, S., Ohshima, T., Sato-Yoshitake, R., Takei, Y., Noda, T., Hirokawa, N., "Altered microtubule organization in small-calibre axons of mice lacking tau protein", Nature Vol 369 1994, pp. 488-491.	
VB		Spittaels, K., Van den Haute, C., Van Dorpe, J., Bruynseels, K., Vandezande, K., Laenen I., Geerts, H., Mercken, M., Sciot R., Van Lommel, Loos, R., Van Leuven, F., "Prominent Axonopathy in the Brain and Spinal Cord of Transgenic Mice Overexpressing Four-Repeat Human tau Protein", American Journal of Pathology, Vol. 155, No. 6 1999, pp. 2153-2165	
VB		Spittaels, K., Van den Haute, C., Van Dorpe, J., et al. " Glycogen Synthase Kinase 3(beta) Phosphorylates Protein Tau and Rescues the Axonopathy in the Central Nervous System of Humanfour-repeat Tau Transgenic Mice, The Journal of Biological Chemistry, Vol 275 No. 52, pp. 41340-41349 2000	
VB		Dawson, H.N., Eyster, M.V., Vitek, M.P., "Tau Distribution in a Human Tau Gene Transgenic/Mouse Tau Knock-Out Model", Society for Neuroscience Vol. 25, p. 790 1999	
VB		Dawson, H.N., Ferreira, A., Eyster, M.V., et al. "Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice", Journal of Cell Science, 114, 1179-1187 2001	

Examiner Signature		Date Considered	02.02.04
-----------------------	---	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.